FDA Guaifenesin Crackdown Based On Adams Labs NDA “Improper” – Petition

FDA's call for the immediate removal of unapproved guaifenesin extended-release drugs from the market "improperly cedes FDA's enforcement discretion to private parties," four law firms maintain in a Nov. 12 citizen petition